JP2016513651A5 - - Google Patents

Download PDF

Info

Publication number
JP2016513651A5
JP2016513651A5 JP2016502107A JP2016502107A JP2016513651A5 JP 2016513651 A5 JP2016513651 A5 JP 2016513651A5 JP 2016502107 A JP2016502107 A JP 2016502107A JP 2016502107 A JP2016502107 A JP 2016502107A JP 2016513651 A5 JP2016513651 A5 JP 2016513651A5
Authority
JP
Japan
Prior art keywords
mol
composition
lipid
cisplatin
peg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016502107A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016513651A (ja
JP6077710B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/026341 external-priority patent/WO2014160337A1/en
Publication of JP2016513651A publication Critical patent/JP2016513651A/ja
Publication of JP2016513651A5 publication Critical patent/JP2016513651A5/ja
Application granted granted Critical
Publication of JP6077710B2 publication Critical patent/JP6077710B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016502107A 2013-03-13 2014-03-13 がん療法のためのリポソームシスプラチン組成物 Expired - Fee Related JP6077710B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361780272P 2013-03-13 2013-03-13
US61/780,272 2013-03-13
PCT/US2014/026341 WO2014160337A1 (en) 2013-03-13 2014-03-13 Liposomal cisplatin compositions for cancer therapy

Publications (3)

Publication Number Publication Date
JP2016513651A JP2016513651A (ja) 2016-05-16
JP2016513651A5 true JP2016513651A5 (cg-RX-API-DMAC7.html) 2016-12-22
JP6077710B2 JP6077710B2 (ja) 2017-02-08

Family

ID=50439522

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016502107A Expired - Fee Related JP6077710B2 (ja) 2013-03-13 2014-03-13 がん療法のためのリポソームシスプラチン組成物

Country Status (8)

Country Link
US (2) US10039716B2 (cg-RX-API-DMAC7.html)
EP (1) EP2968142A1 (cg-RX-API-DMAC7.html)
JP (1) JP6077710B2 (cg-RX-API-DMAC7.html)
CN (1) CN105209017A (cg-RX-API-DMAC7.html)
BR (1) BR112015022415A2 (cg-RX-API-DMAC7.html)
CA (1) CA2903254C (cg-RX-API-DMAC7.html)
MX (1) MX2015012199A (cg-RX-API-DMAC7.html)
WO (1) WO2014160337A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5994049B2 (ja) * 2012-10-01 2016-09-21 兵神装備株式会社 吐出システム
WO2016141167A1 (en) 2015-03-03 2016-09-09 Cureport, Inc. Combination liposomal pharmaceutical formulations
US10736845B2 (en) * 2015-03-03 2020-08-11 Cureport Inc. Dual loaded liposomal pharmaceutical formulations
US20170049701A1 (en) * 2015-08-05 2017-02-23 Steven M. Kushner Clustoidal multilamellar soy lecithin phospholipid structures for transdermal, transmucosal, or oral delivery, improved intestinal absorption, and improved bioavailability of nutrients
EP3352733A1 (en) * 2015-09-21 2018-08-01 Mallinckrodt LLC Improved stability of liposome formulations and uses thereof
SG11201805594PA (en) * 2016-01-07 2018-07-30 Univ Western Health Sciences Formulations for treating bladder cancer
EP3416623B1 (en) 2016-02-15 2021-08-11 University of Georgia Research Foundation, Inc. Ipa-3-loaded liposomes and methods of use thereof
US11266602B2 (en) * 2016-05-16 2022-03-08 Infectious Disease Research Institute PEGylated liposomes and methods of use
CN110381922A (zh) * 2017-01-18 2019-10-25 淡马锡生命科学研究院有限公司 超稳定脂质体增加对有丝分裂细胞的靶向作用
US20190231690A1 (en) * 2017-11-08 2019-08-01 L.E.A.F. Holdings Group Llc Platinum complexes and uses thereof
EP4117686B1 (en) 2020-03-10 2024-12-04 Chung Yuan Christian University Liposome composition and preparation method thereof
TW202345843A (zh) * 2022-04-06 2023-12-01 財團法人國家衛生研究院 脂質奈米顆粒及脂質體

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843473A (en) * 1989-10-20 1998-12-01 Sequus Pharmaceuticals, Inc. Method of treatment of infected tissues
US20020009488A1 (en) * 1995-05-03 2002-01-24 Polymasc Pharmaceuticals Plc Tissue entrapment
EP0929293B1 (en) 1996-08-23 2003-10-22 Sequus Pharmaceuticals, Inc. Liposomes containing a cisplatin compound
PT975329E (pt) 1997-02-05 2005-03-31 Upjohn Co Complexos de lipidos e lipossomas de complexos de platina altamente insoluveis
MXPA02007320A (es) * 2000-01-28 2004-07-30 Alza Corp Liposomas conteniendo un compuesto atrapado en solucion supersaturada.
EP1341497A4 (en) * 2000-11-02 2005-10-19 Smithkline Beecham Corp RECEPTOR-LIPID ANTAGONIST CONJUGATES AND DELIVERY VEHICLES CONTAINING THE SAME
ES2290333T3 (es) * 2001-11-13 2008-02-16 Celator Pharmaceuticals, Inc. Composiciones de vehiculos lipidicos y metodos para la retencion mejorada de farmacos.
EP1674081A1 (de) * 2004-12-23 2006-06-28 KTB Tumorforschungsgesellschaft mbH Herstellung von lipidbasierten Nanopartikeln unter Einsatz einer dualen asymmetrischen Zentrifuge
JP2006248978A (ja) * 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
EP1716870A1 (en) * 2005-04-29 2006-11-02 Bracco Imaging S.p.A. MRI contrast agents endowed with concentration independent responsiveness
US20100034874A1 (en) 2006-12-08 2010-02-11 Katayama Chemical Industries Co., Ltd. Liposome encapsulating ammine-platinum complex at high concentration, and method for production of the liposome

Similar Documents

Publication Publication Date Title
JP2016513651A5 (cg-RX-API-DMAC7.html)
JP6263508B2 (ja) 疾患修飾性抗リウマチ薬（ｄｍａｒｄ）および抗癌剤としてのメトトレキサートの持続性放出製剤
EP2344133B1 (en) A composition of matter comprising liposomes embedded in a polymeric matrix and methods of using same
JP2019006815A5 (cg-RX-API-DMAC7.html)
RU2014120216A (ru) Комбинационные липосомальные композиции для лечения рака
CA2748520A1 (en) Pharmaceutical composition containing an anionic drug, and a production method therefor
JP2014532665A5 (cg-RX-API-DMAC7.html)
WO2010009186A1 (en) Liposome formulation having hydrophilic and hydrophobic pharmaceutical compounds co-encapsulated therein
FI3821887T3 (fi) Mitoksantroni liposomin käyttö ei-hodgkinin lymfooman hoitoon
JP6893245B2 (ja) 脂質ナノ粒子用膜材料組成物
EP3861987A1 (en) Combination medicine comprising drug-encapsulating liposome composition and platinum preparation
JP2019516693A5 (cg-RX-API-DMAC7.html)
JP2014506918A (ja) 抗腫瘍活性物質を含むリポソーム製剤、その調製のための方法、及び、それを含む医薬組成物
JP2018527335A5 (cg-RX-API-DMAC7.html)
JP2009513621A (ja) リポソームを調製する方法及びその使用
JP2018500359A (ja) 表皮成長因子とリポソームのハイブリッド型多層ナノ構造体及びその製造方法
CN107708670A (zh) 磷脂包衣的治疗剂纳米颗粒和有关的方法
EP2231190B1 (en) Particulate drug carriers as desensitizing agents
JP7590774B2 (ja) リポソームドキソルビシン製剤、リポソームドキソルビシン製剤の製造方法、および薬剤としてのリポソームドキソルビシン製剤の使用
JP6322575B2 (ja) 脂質マイクロカプセルのデリバリービヒクルを含む局所用製剤およびその使用
US20160175250A1 (en) Method for Making Liposomes Containing an Active Pharmaceutical Ingredient
TWI391149B (zh) 小粒徑聚乙二醇化微脂體及其製備方法
Singh A Review on Liposome
WO2016013031A1 (en) Liposome composition and method of preparing the liposome
WO2013131164A1 (pt) Composição farmacêutica contendo lipossomas convencionais e lipossomas de circulação prolongada para o tratamento da leishmaniose visceral